• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Luna Innovations Reports Strong First-Quarter 2023 Results

    5/9/23 7:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email

    Reaffirms Full-Year 2023 Outlook

    Q1 Highlights

    • Total revenues of $25.0 million, up 11% year over year
    • Total revenues in constant currency of $25.3 million; up 13% year-over-year
    • Gross margin of 60%, compared to 64% for the prior year
    • Net loss of $1.8 million, compared to net income of $9.6 million for the prior year, which included the gain on sale of Luna Labs
    • Adjusted EBITDA of $0.9 million, compared to $1.7 million for the prior year
    • Adjusted EPS of $0.00, compared to $0.05 for the prior year

    Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced optical technology, today announced its financial results for the three months ended March 31, 2023.

    "I'm pleased that we were able to drive strong revenues in the first quarter, which is cyclically one of our softest revenue quarters," said Scott Graeff, President and Chief Executive Officer of Luna. "Because of the foundational work we did in 2022, we've entered 2023 with an integrated organizational structure, proven systems, and best practices. With those pieces in place, we were able to achieve the top end of our revenue guidance for the quarter.

    "Our charge for 2023 will be to continue to drive operating excellence that will help to set the stage for greater expansion into new markets where we can deliver our superior capabilities and capture share. Given our current position, we're pleased to be able to reaffirm our outlook for 2023 revenue and adjusted EBITDA."

    First-Quarter Fiscal 2023 Financial Summary

    Highlights of the financial results for the three months ended March 31, 2023 are:

     

     

    Three Months Ended March 31,

     

    Change

    (in thousands, except share and per share data)

     

     

    2023

     

     

     

    2022

     

     

     

    Revenues

     

    $

    25,045

     

     

    $

    22,481

     

     

    11

     

    %

     

     

     

     

     

     

     

    Gross profit

     

     

    14,973

     

     

     

    14,279

     

     

    5

     

    %

    Gross margin

     

     

    60

    %

     

     

    64

    %

     

     

     

     

     

     

     

     

    Operating expense

     

     

    17,105

     

     

     

    16,645

     

     

    3

     

    %

    Operating loss

     

     

    (2,132

    )

     

     

    (2,366

    )

     

     

     

    Operating margin

     

     

    (9

    )%

     

     

    (11

    )%

     

     

     

     

     

     

     

     

     

    Other expense, net and income tax benefit

     

     

    290

     

     

     

    1,023

     

     

     

     

     

     

     

     

     

     

     

     

    Net loss from continuing operations

     

    $

    (1,842

    )

     

    $

    (1,343

    )

     

     

     

     

     

     

     

     

     

     

     

    Income from discontinued operations, net of tax of $4,139

     

     

    —

     

     

     

    10,924

     

     

     

     

     

     

     

     

     

     

     

     

    Net (loss)/income

     

    $

    (1,842

    )

     

    $

    9,581

     

     

     

     

     

     

     

     

     

     

     

     

    Income per diluted share (EPS)

     

    $

    (0.06

    )

     

    $

    0.30

     

     

     

     

    Adjusted EPS

     

    $

    0.00

     

     

    $

    0.05

     

     

     

     

    Diluted weighted average shares outstanding

     

     

    33,331,745

     

     

     

    32,243,082

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA

     

    $

    854

     

     

    $

    1,721

     

     

    (50

    )

    %

    A reconciliation of Adjusted EPS, Adjusted EBITDA and revenues in constant currency to the nearest comparable figures under generally accepted accounting principles ("GAAP") can be found in the schedules included in this release.

    Revenues for the three months ended March 31, 2023 increased 11% compared to the prior-year period; 13% on a constant currency basis.

    Gross margin was 60% for the three months ended March 31, 2023, compared to 64% for the three months ended March 31, 2022, driven primarily by product mix and the Lios acquisition. Operating loss and margin were $2.1 million and 9% of total revenues, respectively, for the three months ended March 31, 2023, compared to an operating loss of $2.4 million dollars and 11% of total revenues, respectively, for the three months ended March 31, 2022.

    Net loss was $1.8 million, or $0.06 per fully diluted share, for the three months ended March 31, 2023, compared to net income of $9.6 million, or $0.30 per fully diluted share, for the three months ended March 31, 2022. Adjusted EPS was $0.00 for the three months ended March 31, 2023 compared to $0.05 for the three months ended March 31, 2022.

    Adjusted EBITDA was $0.9 million for three months ended March 31, 2023, compared to $1.7 million for the three months ended March 31, 2022.

    Q1 and Recent Business Highlights

    • Realized strong, double-digit revenue growth for communications test and Terahertz product lines
    • Announced a significant contract to provide temperature, depth and acoustic monitoring for an innovative power generation project that will deliver clean energy to a major metropolitan area in the Northeast U.S.
    • Announced large, new contract with Dominion Energy to provide monitoring services for the largest offshore wind project in the United States
    • Won a contract for industrial battery storage monitoring for a leading European manufacturer of electric vehicle batteries
    • Experienced high levels of activity and customer engagement at industry trade shows OFC and Photonics West

    2023 Full-Year Outlook

    Luna is reaffirming the 2023 revenue and adjusted EBITDA outlook it originally provided on March 14, 2023:

    • Total revenue of $125 million to $130 million for the full year 2023
    • Adjusted EBITDA of $14 million to $18 million for the full year 2023

    In addition, Luna expects total revenues in the range of $29 million to $31 million for the second quarter 2023.

    Luna is not providing an outlook for net income, which is the most directly comparable GAAP measure to Adjusted EBITDA, because changes in the items that Luna excludes from net income to calculate Adjusted EBITDA, such as share-based compensation, tax expense, and significant non-recurring charges, among other things, can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Luna's routine operating activities.

    The outlook above does not include any future acquisitions, divestitures, or unanticipated events.

    Non-GAAP Financial Measures

    In evaluating the operating performance of its business, Luna's management considers Adjusted EBITDA, Adjusted EPS and revenue measured on a constant currency basis, which are non-GAAP financial measures. Adjusted EBITDA and Adjusted EPS exclude certain charges and income that are required by GAAP. Adjusted EBITDA and Adjusted EPS provide useful information to both management and investors by excluding the effect of certain non-cash expenses and items that Luna believes may not be indicative of its operating performance, because either they are unusual and Luna does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course.

    The Company calculates revenue measured on a constant currency basis by translating its foreign revenues for the relevant period in U.S. dollars at the average exchange rate in effect for the comparable prior year period. The Company presents revenue in this manner because it is a global company that transacts business in multiple currencies and reports financial information in U.S. dollars. Foreign currency exchange rate fluctuations affect the amounts reported by the Company in U.S. dollars with respect to its foreign revenues. Exchange rate fluctuations can have a significant effect on reported revenues. The Company believes presenting constant currency revenue information provides useful information to investors, as it provides information to assess how its businesses performed excluding the effects of changes in foreign currency exchange rates and assists investors in evaluating the effectiveness of the Company's operations and underlying business trends in a manner that is consistent with management's evaluation of business performance.

    Adjusted EBITDA, Adjusted EPS and revenue measured on a constant currency basis should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Adjusted EBITDA and Adjusted EPS have been reconciled to the nearest GAAP measure in the table following the financial statements attached to this press release.

    Conference Call Information

    As previously announced, Luna will conduct an investor conference call at 8:00 am (ET) today, May 9, 2023, to discuss its financial results for the three months ended March 31, 2023. The investor conference call will be available via live webcast on the Luna website at www.lunainc.com under the tab "Investor Relations." To participate by telephone, the domestic dial-in number is 1.833.630.1956 .and the international dial-in number is 1.412.317.1837. Participants should ask to join the Luna Innovations Incorporated conference call and are advised to dial in at least fifteen minutes prior to the call. A replay of the conference call will be available on the company's website under "Webcasts and Presentations" for 30 days following the conference call.

    About Luna

    Luna Innovations Incorporated (www.lunainc.com) is a leader in optical technology, providing unique capabilities in high-performance, fiber optic-based, test products for the telecommunications industry and distributed fiber optic-based sensing for a multitude of industries. Luna's business model is designed to accelerate the process of bringing new and innovative technologies to market.

    Forward-Looking Statements

    The statements in this release that are not historical facts constitute "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include Luna's expectations regarding its projected full year 2023 and second quarter of 2023 financial results and outlook, greater expansion into new markets and the Company's ability to capitalize on growth trends. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of Luna may differ materially from the future results, performance, and/or achievements expressed or implied by these forward-looking statements as a result of a number of factors. These factors include, without limitation, failure of demand for Luna's products and services to meet expectations, failure of target market to grow and expand, technological and strategic challenges, uncertainties related to the ultimate impact of the COVID-19 pandemic and those risks and uncertainties set forth in Luna's Form 10-Q for the quarter ended March 31, 2023, and Luna's other periodic reports and filings with the Securities and Exchange Commission ("SEC"). Such filings are available on the SEC's website at www.sec.gov and on Luna's website at www.lunainc.com. The statements made in this release are based on information available to Luna as of the date of this release and Luna undertakes no obligation to update any of the forward-looking statements after the date of this release.

    Luna Innovations Incorporated

    Consolidated Balance Sheets (Unaudited)

    (in thousands, except share data)

     

     

    March 31, 2023

     

    December 31, 2022

     

    (unaudited)

     

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    3,559

     

     

    $

    6,024

     

    Accounts receivable, net

     

    31,924

     

     

     

    33,249

     

    Contract assets

     

    9,001

     

     

     

    7,691

     

    Inventory

     

    39,675

     

     

     

    36,582

     

    Prepaid expenses and other current assets

     

    5,815

     

     

     

    4,328

     

    Total current assets

     

    89,974

     

     

     

    87,874

     

    Property and equipment, net

     

    4,691

     

     

     

    4,893

     

    Intangible assets, net

     

    18,125

     

     

     

    18,750

     

    Goodwill

     

    27,208

     

     

     

    26,927

     

    Operating lease right-of-use assets

     

    4,293

     

     

     

    4,661

     

    Other non-current assets

     

    3,295

     

     

     

    3,255

     

    Deferred tax asset

     

    4,548

     

     

     

    4,647

     

    Total assets

    $

    152,134

     

     

    $

    151,007

     

    Liabilities and stockholders' equity

     

     

     

    Liabilities:

     

     

     

    Current liabilities:

     

     

     

    Current portion of long-term debt obligations

    $

    2,750

     

     

    $

    2,500

     

    Accounts payable

     

    5,578

     

     

     

    8,109

     

    Accrued and other current liabilities

     

    16,273

     

     

     

    16,694

     

    Contract liabilities

     

    5,942

     

     

     

    4,089

     

    Current portion of operating lease liabilities

     

    2,116

     

     

     

    2,239

     

    Total current liabilities

     

    32,659

     

     

     

    33,631

     

    Long-term debt obligations, net of current portion

     

    22,480

     

     

     

    20,726

     

    Long-term portion of operating lease liabilities

     

    2,495

     

     

     

    2,804

     

    Other long-term liabilities

     

    432

     

     

     

    444

     

    Total liabilities

     

    58,066

     

     

     

    57,605

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock, par value $0.001, 100,000,000 shares authorized, 35,227,817 and 34,901,954 shares issued, 33,396,326 and 33,105,080 shares outstanding at March 31, 2023 and December 31, 2022, respectively

     

    35

     

     

     

    35

     

    Treasury stock at cost, 1,831,491 and 1,796,862 shares at March 31, 2023 and December 31, 2022, respectively

     

    (5,949

    )

     

     

    (5,607

    )

    Additional paid-in capital

     

    106,624

     

     

     

    104,893

     

    Accumulated deficit

     

    (4,138

    )

     

     

    (2,296

    )

    Accumulated other comprehensive loss

     

    (2,504

    )

     

     

    (3,623

    )

    Total stockholders' equity

     

    94,068

     

     

     

    93,402

     

    Total liabilities and stockholders' equity

    $

    152,134

     

     

    $

    151,007

     

    Luna Innovations Incorporated

    Consolidated Statements of Operations (Unaudited)

    (in thousands, except share and per share data)

     

     

    Three Months Ended March 31,

     

     

    2023

     

     

     

    2022

     

     

     

    Revenues

    $

    25,045

     

     

    $

    22,481

     

    Cost of revenues

     

    10,072

     

     

     

    8,202

     

    Gross profit

     

    14,973

     

     

     

    14,279

     

    Operating expense:

     

     

     

    Selling, general and administrative

     

    13,296

     

     

     

    13,281

     

    Research, development and engineering

     

    2,817

     

     

     

    2,543

     

    Amortization of intangible assets

     

    992

     

     

     

    821

     

    Total operating expense

     

    17,105

     

     

     

    16,645

     

    Operating loss

     

    (2,132

    )

     

     

    (2,366

    )

    Other income/(expense):

     

     

     

    Other income

     

    92

     

     

     

    21

     

    Interest expense, net

     

    (369

    )

     

     

    (113

    )

    Total other expense, net

     

    (277

    )

     

     

    (92

    )

    Loss from continuing operations before income taxes

     

    (2,409

    )

     

     

    (2,458

    )

    Income tax benefit

     

    (567

    )

     

     

    (1,115

    )

    Net loss from continuing operations

     

    (1,842

    )

     

     

    (1,343

    )

    Income from discontinued operations, net of tax of $1,022

     

    —

     

     

     

    3

     

    Gain on sale of discontinued operations, net of tax of $3,117

     

    —

     

     

     

    10,921

     

    Net income from discontinued operations

     

    —

     

     

     

    10,924

     

    Net (loss)/income

    $

    (1,842

    )

     

    $

    9,581

     

    Net loss per share from continuing operations:

     

     

     

    Basic

    $

    (0.06

    )

     

    $

    (0.04

    )

    Diluted

    $

    (0.06

    )

     

    $

    (0.04

    )

    Net income per share from discontinued operations:

     

     

     

    Basic

    $

    —

     

     

    $

    0.34

     

    Diluted

    $

    —

     

     

    $

    0.34

     

    Net (loss)/income per share attributable to common stockholders:

     

     

     

    Basic

    $

    (0.06

    )

     

    $

    0.30

     

    Diluted

    $

    (0.06

    )

     

    $

    0.30

     

    Weighted average shares:

     

     

     

    Basic

     

    33,331,745

     

     

     

    32,243,082

     

    Diluted

     

    33,331,745

     

     

     

    32,243,082

     

    Luna Innovations Incorporated

    Consolidated Statements of Cash Flows (Unaudited)

    (in thousands)

     

     

    Three Months Ended March 31,

     

     

    2023

     

     

     

    2022

     

     

     

    Cash flows used in by operating activities

     

     

     

    Net (loss)/income

    $

    (1,842

    )

     

    $

    9,581

     

    Adjustments to reconcile net (loss)/income to net cash used in operating activities

     

     

     

    Depreciation and amortization

     

    1,417

     

     

     

    1,179

     

    Share-based compensation

     

    1,054

     

     

     

    1,132

     

    Loss on disposal of property and equipment

     

    51

     

     

     

    —

     

    Gain from discontinued operations, net of tax

     

    —

     

     

     

    (10,921

    )

    Deferred taxes

     

    99

     

     

     

    220

     

    Change in assets and liabilities

     

     

     

    Accounts receivable

     

    1,596

     

     

     

    (1,795

    )

    Contract assets

     

    (1,250

    )

     

     

    (1,144

    )

    Inventory

     

    (2,619

    )

     

     

    (1,416

    )

    Other current assets

     

    (1,573

    )

     

     

    (1,636

    )

    Other long-term assets

     

    (54

    )

     

     

    2

     

    Accounts payable and accrued and other current liabilities

     

    (3,173

    )

     

     

    2,287

     

    Contract liabilities

     

    1,785

     

     

     

    171

     

    Other long term-liabilities

     

    —

     

     

     

    (33

    )

    Net cash used in operating activities

     

    (4,509

    )

     

     

    (2,373

    )

    Cash flows used in investing activities

     

     

     

    Acquisition of property and equipment

     

    (478

    )

     

     

    (915

    )

    Intangible property costs

     

    (32

    )

     

     

    —

     

    Proceeds from sale of property and equipment

     

    —

     

     

     

    25

     

    Proceeds from sale of discontinued operations

     

    —

     

     

     

    12,973

     

    Acquisition of Luna Innovations Germany GmbH

     

    —

     

     

     

    (22,085

    )

    Other

     

    —

     

     

     

    38

     

    Net cash used in investing activities

     

    (510

    )

     

     

    (9,964

    )

    Cash flows provided by financing activities

     

     

     

    Payments on finance lease obligations

     

    (12

    )

     

     

    (12

    )

    Proceeds from borrowings under debt obligations

     

    2,500

     

     

     

    7,450

     

    Payments of debt obligations

     

    (496

    )

     

     

    (1,036

    )

    Repurchase of common stock

     

    (342

    )

     

     

    (278

    )

    Proceeds from ESPP

     

    —

     

     

     

    85

     

    Proceeds from the exercise of stock options

     

    834

     

     

     

    220

     

    Net cash provided by financing activities

     

    2,484

     

     

     

    6,429

     

    Effect of exchange rate changes on cash and cash equivalents

     

    70

     

     

     

    (432

    )

    Net decrease in cash and cash equivalents

     

    (2,465

    )

     

     

    (6,340

    )

    Cash and cash equivalents-beginning of period

     

    6,024

     

     

     

    17,128

     

    Cash and cash equivalents-end of period

    $

    3,559

     

     

    $

    10,788

     

    Luna Innovations Incorporated

    Reconciliation of Net (Loss)/Income to EBITDA and Adjusted EBITDA

    (in thousands)

     

     

    Three Months Ended March 31,

     

     

    2023

     

     

     

    2022

     

     

     

    Net (loss)/income

    $

    (1,842

    )

     

    $

    9,581

     

    Net income from discontinued operations

     

    —

     

     

     

    10,924

     

    Net loss from continuing operations

     

    (1,842

    )

     

     

    (1,343

    )

    Interest expense, net

     

    369

     

     

     

    113

     

    Income tax benefit

     

    (567

    )

     

     

    (1,115

    )

    Depreciation and amortization

     

    1,417

     

     

     

    1,156

     

    EBITDA

     

    (623

    )

     

     

    (1,189

    )

    Share-based compensation

     

    1,054

     

     

     

    1,066

     

    Integration and transaction expense

     

    89

     

     

     

    1,844

     

    Other non-recurring charges (1)

     

    334

     

     

     

    —

     

    Adjusted EBITDA

    $

    854

     

     

    $

    1,721

     

     

    (1) - Other non-recurring charges primarily include facility consolidation and one-time insurance deductible.

    Luna Innovations Incorporated

    Reconciliation of Net (Loss)/Income to Adjusted EPS

    (in thousands, except per share data)

     

     

    Three Months Ended March 31,

     

     

    2023

     

     

     

    2022

     

     

     

    Net (loss)/income

    $

    (1,842

    )

     

    $

    9,581

     

    Net income from discontinued operations

     

    —

     

     

     

    10,924

     

    Net loss from continuing operations

     

    (1,842

    )

     

     

    (1,343

    )

    Share-based compensation

     

    1,054

     

     

     

    1,066

     

    Integration and transaction expense

     

    89

     

     

     

    1,844

     

    Amortization of intangible assets

     

    992

     

     

     

    821

     

    Other non-recurring charges (1)

     

    334

     

     

     

    —

     

    Income tax effect on adjustments

     

    (617

    )

     

     

    (933

    )

    Adjusted income from continuing operations

    $

    10

     

     

    $

    1,455

     

     

     

     

     

     

     

     

     

    Adjusted EPS

    $

    0.00

     

     

    $

    0.05

     

     

     

     

     

    Adjusted weighted average shares (in thousands):

     

     

     

    Diluted

     

    33,332

     

     

     

    32,243

     

     

    (1) - Other non-recurring charges primarily include facility consolidation and one-time insurance deductible.

    Luna Innovations Incorporated

    Reconciliation of Revenues to Constant Currency Revenues

    (in thousands)

     

     

    Three Months Ended

    March 31, 2023

    GAAP revenues

    $

    25,045

    Effect of foreign exchange

     

    256

    Constant currency revenues

    $

    25,301

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005382/en/

    Get the next $LUNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    SEC Filings

    See more
    • Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/27/25 10:26:44 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

      SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/14/25 1:56:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/6/25 8:30:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 12:32:28 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 8:39:20 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/12/24 4:02:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $LUNA
    Leadership Updates

    Live Leadership Updates

    See more

    $LUNA
    Financials

    Live finance-specific insights

    See more

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Luna Announces Strong Start to 2025 with Substantial Bookings Growth

      Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber optic-based technology, today announced select preliminary operating and financial metrics for the first quarter ended March 31, 2025, showcasing significant year-over-year bookings growth, continued gross margin expansion, and sustained execution on cost containment initiatives. "We are pleased to report a strong start to 2025, with sharp improvements in bookings, margin performance, and working capital management," said the Company's President, Chief Executive Officer, Kevin Ilcisin. "Our continued focus on operational discipline, customer alignment, and profitable growth is positioning

      5/20/25 8:48:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market. "Luna star

      1/27/25 10:24:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Resignation of Pamela Coe

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

      12/27/24 4:40:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

      Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

      10/16/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

      3/12/24 4:20:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

      Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

      12/21/23 9:34:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Acquires Silixa

      Strengthens Portfolio of Distributed Fiber Optic Sensing Solutions Adds Significant New Growth Markets and Applications and Further Expands Global Footprint Conference Call Scheduled for Today, December 21st, at 11:00 AM ET Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the strategic acquisition of Silixa, a UK-based leader in distributed fiber optic sensing solutions. The acquisition further propels Luna's position in the fiber optic sensing market, adding capabilities in distributed acoustic sensing (DAS), distributed temperature sensing (DTS) and distributed strain sensing (DSS) that offer enhanced performance

      12/21/23 9:32:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:44:17 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:43:48 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      12/26/24 5:52:51 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Stifel initiated coverage on Luna Innovations with a new price target

      Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

      7/28/23 7:35:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Needham initiated coverage on Luna Innovations with a new price target

      Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

      5/22/23 7:57:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations downgraded by Northland Capital with a new price target

      Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

      3/15/23 8:52:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care